Natural compounds with P2X7 receptor-modulating properties

Purinergic Signalling

Volumn 10, Issue 2, 2014, Pages 313-326

  Fischer, Wolfgang ^a   Urban, Nicole ^a   Immig, Kerstin ^a   Franke, Heike ^a   Schaefer, Michael ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

calcium influx; Dye permeability; Ion channel coupled purinergic receptors; P2X7; Pore formation

Indexed keywords

3 [[5 (2, 3 DICHLOROPHENYL) 1H TETRAZOL 1 YL] METHYL] PYRIDINE; ADENOSINE TRIPHOSPHATE; AGELASIMINE; PURINERGIC P2X7 RECEPTOR; TENIPOSIDE; UNCLASSIFIED DRUG; PURINERGIC P2X RECEPTOR AGONIST; PURINERGIC P2X RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCEIN-AM ASSAY; CELL DAMAGE; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE; FLUOROMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NEUROPROTECTION; NONHUMAN; ANIMAL; CONFOCAL MICROSCOPY; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELL LINE; METABOLISM; RAT;

ANIMALS; DRUG EVALUATION, PRECLINICAL; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELLS; HUMANS; MICE; MICROSCOPY, CONFOCAL; PURINERGIC P2X RECEPTOR AGONISTS; PURINERGIC P2X RECEPTOR ANTAGONISTS; RATS; RECEPTORS, PURINERGIC P2X7;

EID: 84901834226     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-013-9392-1     Document Type: Article

References (56)

1. Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63(3): 641-683.
2. Kaczmarek-Hájek K, Lörinczi E, Hausmann R, Nicke A (2012) Molecular and functional properties of P2X receptors-recent progress and persisting challenges. Purinergic Signal 8(3): 375-417.
3. Volonté C, Apolloni S, Skaper SD, Burnstock G (2012) P2X7 receptors: channels, pores and more. CNS Neurol Disord Drug Targets 11(6): 705-721.
4. Jiang LH, Baldwin JM, Roger S, Baldwin SA (2013) Insights into the molecular mechanisms underlying mammalian P2X7 receptor functions and contributions in diseases, revealed by structural modeling and single nucleotide polymorphisms. Front Pharmacol 4: 55.
5. 7 receptor-pannexin connection to dye uptake and IL-1β release. Purinergic Signal 5(2): 129-137.
6. Khakh BS, North RA (2012) Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron 76(1): 51-69.
7. 7 purinergic receptor: from physiology to neuronal disorders. FASEB J 24(2): 337-345.
8. Burnstock G, Kennedy C (2011) P2X receptors in health and disease. Adv Pharmacol 61: 333-372.
9. Wiley JS, Sluyter R, Gu BJ, Stokes L, Fuller SJ (2011) The human P2X7 receptor and its role in innate immunity. Tissue Antigens 78(5): 321-332.
10. Sluyter R, Stokes L (2011) Significance of P2X7 receptor variants to human health and disease. Recent Pat DNA Gene Seq 5(1): 41-54.
11. 7 receptors. J Biol Chem 276(1): 125-132.
12. 7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 168(12): 6436-6445.
13. 7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114(3): 386-396.
14. 7 receptor as a therapeutic target. Expert Opin Ther Targets 12(5): 647-661.
15. Gunosewoyo H, Kassiou M (2010) P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat 20(5): 625-646.
16. Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, Wang X, Gupta P, Mebus CA (2012) Efficacy and safety of CE-224, 535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol 39(4): 720-727.
17. Regen T, van Rossum D, Scheffel J, Kastriti ME, Revelo NH, Prinz M, Brück W, Hanisch UK (2011) CD14 and TRIF govern distinct responsiveness and responses in mouse microglial TLR4 challenges by structural variants of LPS. Brain Behav Immun 25(5): 957-970.
18. Nelson DW, Sarris K, Kalvin DM, Namovic MT, Grayson G, Donnelly-Roberts DL, Harris R, Honore P, Jarvis MF, Faltynek CR, Carroll WA (2008) Structure-activity relationship studies on N′-aryl carbohydrazide P2X7 antagonists. J Med Chem 51(10): 3030-3044.
19. Michel AD, Chambers LJ, Clay WC, Condreay JP, Walter DS, Chessell IP (2007) Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br J Pharmacol 151(1): 103-114.
20. Nörenberg W, Sobottka H, Hempel C, Plötz T, Fischer W, Schmalzing G, Schaefer M (2012) Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors. Br J Pharmacol 167(1): 48-66.
21. 7). Science 272(5262): 735-738.
22. 7 receptor antagonists for chronic inflammation and pain. Purinergic Signal 5(1): 63-73.
23. 7 receptor. From lead identification to drug development. J Med Chem 52(10): 3123-3141.
24. 7 receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat CNS Drug Discov 5(1): 35-45.
25. Sanz JM, Di Virgilio F (2000) Kinetics and mechanism of ATP-dependent IL-1 beta release from microglial cells. J Immunol 164(9): 4893-4898.
26. Arbeloa J, Pérez-Samartín A, Gottlieb M, Matute C (2012) P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol Dis 45(3): 954-961.
27. 7 receptor is neuroprotective in an animal model of Alzheimer's disease. Neuroreport 19(17): 1715-1719.
28. Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, Iwamaru Y, Kitani H, Hashimoto M (2010) P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 58(2): 91-96.
29. Le Feuvre RA, Brough D, Touzani O, Rothwell NJ (2003) Role of P2X7 receptors in ischemic and excitotoxic brain injury in vivo. J Cereb Blood Flow Metab 23(3): 381-384.
30. 7 receptors. Cell Tissue Res 321(3): 411-418.
31. White N, Knight GE, Butler PE, Burnstock G (2009) An in vivo model of melanoma: treatment with ATP. Purinergic Signal 5(3): 327-333.
32. Deli T, Csernoch L (2008) Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors. Pathol Oncol Res 14(3): 219-231.
33. Farrell AW, Gadeock S, Pupovac A, Wang B, Jalilian I, Ranson M, Sluyter R (2010) P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells. Biochim Biophys Acta 1800(11): 1173-1182.
34. 7: a growth-promoting receptor-implications for cancer. Purinergic Signal 5(2): 251-256.
35. Stagg J, Smyth MJ (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29(39): 5346-5358.
36. Ryu JK, Jantaratnotai N, Serrano-Perez MC, McGeer PL, McLarnon JG (2011) Block of purinergic P2X7 receptors inhibits tumor growth in a C6 glioma brain tumor animal model. J Neuropathol Exp Neurol 70(1): 13-22.
37. 7 receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene 30(18): 2108-2122.
38. You V (2005) Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Des 11(13): 1695-1717.
39. Li J, Chen W, Zhang P, Li N (2006) Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma. World J Surg Oncol 4: 41.
40. Rivera GK, Pui CH, Santana VM, Pratt CB, Crist WM (1994) Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemother Pharmacol 34(Suppl): S89-S95.
41. Hande KR (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400(1-3): 173-184.
42. Rodman JH, Furman WL, Sunderland M, Rivera G, Evans WE (1993) Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. J Clin Oncol 11(2): 287-293.
43. Nagai N, Shikii T, Mihara K, Ogata H, Sasaki Y (1998) Improved high-performance liquid chromatographic analysis of teniposide in human plasma. J Chromatogr B Biomed Sci Appl 709(2): 315-319.
44. Lv M, Xu H (2011) Recent advances in semisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: an update (2008-2010). Mini Rev Med Chem 11(10): 901-909.
45. Gordaliza M (2009) Terpenyl-purines from the sea. Mar Drugs 7(4): 833-849.
46. Proszenyák Á, Charnock C, Hedner E, Larsson R, Bohlin L, Gundersen LL (2007) Synthesis, antimicrobial and antineoplastic activities for agelasine and agelasimine analogs with a beta-cyclocitral derived substituent. Arch Pharm Chem Life Sci 340(12): 625-634.
47. Vik A, Hedner E, Charnock C, Tangen LW, Samuelsen Ø, Larsson R, Bohlin L, Gundersen LL (2007) Antimicrobial and cytotoxic activity of agelasine and agelasimine analogs. Bioorg Med Chem 15(12): 4016-4037.
48. Vik A, Proszenyák Á, Vermeersch M, Cos P, Maes L, Gundersen LL (2009) Screening of agelasine D and analogs for inhibitory activity against pathogenic protozoa; identification of hits for visceral leishmaniasis and Chagas disease. Molecules 14(1): 279-288.
49. Sjögren M, Dahlström M, Hedner E, Jonsson PR, Vik A, Gundersen LL, Bohlin L (2008) Antifouling activity of the sponge metabolite agelasine D and synthesised analogs on Balanus improvisus. Biofouling 24(4): 251-258.
50. Roggen H, Charnock C, Burman R, Felth J, Larsson R, Bohlin L, Gundersen LL (2011) Antimicrobial and antineoplastic activities of agelasine analogs modified in the purine 2-position. Arch Pharm Chem Life Sci 344(1): 50-55.
51. 2+ concentration and induces apoptosis in human breast cancer cells (MCF-7). Cancer Chemother Pharmacol 69(1): 71-83.
52. Biswas D, Qureshi OS, Lee WY, Croudace JE, Mura M, Lammas DA (2008) ATP-induced autophagy is associated with rapid killing of intracellular mycobacteria within human monocytes/macrophages. BMC Immunol 9: 35. doi: 10. 1186/1471-2172-9-35.
53. Han QB, Wang YL, Yang L, Tso TF, Qiao CF, Song JZ, Xu LJ, Chen SL, Yang DJ, Xu HX (2006) Cytotoxic polyprenylated xanthones from the resin of Garcinia hanburyi. Chem Pharm Bull (Tokyo) 54(2): 265-267.
54. Zhai D, Jin C, Shiau CW, Kitada S, Satterthwait AC, Reed JC (2008) Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 7(6): 1639-1646.
55. Deng YX, Pan SL, Zhao SY, Wu MQ, Sun ZQ, Chen XH, Shao ZY (2012) Cytotoxic alkoxylated xanthones from the resin of Garcinia hanburyi. Fitoterapia 83(8): 1548-1552.
56. 7 receptor. Br J Pharmacol 153(4): 737-750.